相关实验视频

Updated: Jul 29, 2025

Flow Cytometry-based Drug Screening System for the Identification of Small Molecules That Promote Cellular Differentiation of Glioblastoma Stem Cells

Flow Cytometry-based Drug Screening System for the Identification of Small Molecules That Promote Cellular Differentiation of Glioblastoma Stem Cells

Published on: January 10, 2018

一种新型的合成烯酸衍生物通过调节细胞周期G2/M停止来抑制质瘤细胞的增殖

Tai-Hsin Tsai^1,2,3,4, Cheng-Yu Tsai^1,2,3, Sin-Hua Moi^1,2,3

¹Division of Neurosurgery, Department of Surgery, Kaohsiung Medical University Hospital, Kaohsiung 80756, Taiwan.

Pharmaceuticals (Basel, Switzerland)

|May 27, 2023

概括

2-Cyano-3,12-dioxooleana-1,9(11)-dien-28-oic acid-9,11-dihydro-trifluoroethyl amide (CDDO-dhTFEA) 显示出作为一种抗癌治疗的前景. 这种化合物有效地抑制了质母细胞瘤细胞增殖,并在体外诱导细胞循环停止.

科学领域:

在瘤学瘤学.
分子生物学分子生物学
药理学药理学是指药理学的学科.

背景情况:

2-Cyano-3,12-dioxooleana-1,9(11)-dien-28-oic acid-9,11-dihydro-trifluoroethyl amide (CDDO-dhTFEA) 显示出已知的抗氧化和抗炎性质. 这是一种具有抗氧化和抗炎性质的蛋白质.
CDDO-dhTFEA的潜在抗癌作用在很大程度上仍未被探索.

研究的目的:

研究CDDO-dhTFEA作为潜在的抗癌治疗剂的疗效.
评估CDDO-dhTFEA对质母细胞瘤细胞系的影响.

主要方法:

对U87MG和GBM8401质母细胞瘤细胞系进行了实验.
在CDDO-dhTFEA治疗后,分析了细胞增殖,DNA合成和细胞周期进展.
评估了与细胞周期相关的基因表达和蛋白质调节.

主要成果:

根据时间和剂量,CDDO-dhTFEA显著降低了质母细胞细胞的增殖.
该化合物在U87MG和GBM8401细胞中增加了DNA合成.
CDDO-dhTFEA诱导了G2/M细胞周期停止和线粒体延迟,与抑制的增殖相关.

结论:

在实验室中,CDDO-dhTFEA对质母细胞瘤细胞具有显著的抗癌活性.
该机制涉及G2/M细胞周期蛋白和基因表达的调节,导致增殖抑制.
CDDO-dhTFEA代表了质母细胞瘤治疗的潜在治疗候选者.

关键词:

这是CDDO-dhTFEA.在RTA-dh404中使用.细胞循环停止细胞循环停止质母细胞瘤是一种质母细胞瘤.

更多相关视频

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Published on: May 14, 2016

A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells

A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells

Published on: March 28, 2021

相关概念视频

Inhibition of Cdk Activity

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...